Compare DVA & EMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DVA | EMN |
|---|---|---|
| Founded | 1994 | 1920 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 8.5B |
| IPO Year | 2002 | 1996 |
| Metric | DVA | EMN |
|---|---|---|
| Price | $200.04 | $71.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $156.75 | $79.31 |
| AVG Volume (30 Days) | 867.0K | ★ 1.0M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.77% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.87 | 0.93 |
| Revenue | ★ $13,643,069,000.00 | $8,752,000,000.00 |
| Revenue This Year | $3.85 | $3.06 |
| Revenue Next Year | $3.07 | $3.47 |
| P/E Ratio | ★ $69.44 | $77.09 |
| Revenue Growth | ★ 6.46 | N/A |
| 52 Week Low | $101.00 | $56.11 |
| 52 Week High | $202.69 | $83.47 |
| Indicator | DVA | EMN |
|---|---|---|
| Relative Strength Index (RSI) | 76.16 | 43.22 |
| Support Level | $145.58 | $70.39 |
| Resistance Level | N/A | $78.41 |
| Average True Range (ATR) | 7.51 | 2.39 |
| MACD | 2.87 | -0.36 |
| Stochastic Oscillator | 96.49 | 19.69 |
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.